Clinical trials: HELLP Syndrome Second Trimester
Preeclampsia, Severe Preeclampsia
Complement Regulation to Undo Systemic Harm in Preeclampsia
This is a Phase II, single arm, open-label study to determine if treatment with eculizumab prolongs pregnancy compared to historical controls in women with preeclampsia between 23-30 weeks gestation.
- Conditions
- Preeclampsia, Severe Preeclampsia, Eculizumab, HELLP
- Trial name
- CRUSH (NCT04725812)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cedars-Sinai Medical Center
Pre-Eclampsia, Fetal Growth Retardation
Doppler and Biological Second Trimester Placental Insufficiency Screening
To assess the role of uterine artery and maternal serum leptin and lipids and their combination in screening for pre-eclampsia and small-for-gestational-age (SGA) fetuses at 20-24 weeks of gestation
- Conditions
- Pre-Eclampsia, Fetal Growth Retardation, Placental Insufficiency
- Trial name
- ARTULEP (NCT00465634)
- Where
- France
- Volunteers
- 235 people
- Sponsor
- University Hospital, Tours